The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 276-281

  Eisenhauer, Eric L ^a   Abu Rustum, Nadeem R ^a   Sonoda, Yukio ^a   Aghajanian, Carol ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cytoreduction; Debulking; Ovarian cancer; Platinum sensitivity; Survival

Indexed keywords

PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TAXOIDS;

EID: 38649086712     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.022     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
3. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
4. Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buchsbaum H.J., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9 (1991) 1138-1150
5. Hoskins W.J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55 3 Pt 2 (1994) S91-S96
6. Makar A.P., Baekelandt M., Trope C.G., and Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56 (1995) 175-180
7. Le T., Krepart G.V., Lotocki R.J., and Heywood M.S. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecol Oncol 67 (1997) 208-214
8. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
9. Bristow R.E., and Montz F.J. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83 (2001) 39-48
10. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 (2003) 390-396
11. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 (1996) 361-364
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
13. McNutt L.A., Wu C., Xue X., and Hafner J.P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 157 (2003) 940-943
14. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159 (2004) 702-706
15. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
17. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
18. Meigs J.V. Tumors of the female pelvic organs (1934), Macmillan, New York
19. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
20. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979 [discussion 980]
21. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 (2006) 559-564
22. Allen D.G., Heintz A.P., and Touw F.W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16 (1995) 349-356
23. Goldie J.H., and Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 (1979) 1727-1733
24. Berchuck A., Iversen E.S., Lancaster J.M., Dressman H.K., West M., Nevins J.R., et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190 (2004) 910-925
25. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 (1991) 389-393
26. Markman M., and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10 (1992) 513-514
27. Bristow R.E., Eisenhauer E.L., Santillan A., and Chi D.S. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104 (2007) 480-490
28. Cliby W.A., Aletti G.D., Wilson T.O., and Podratz K.C. Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only?. Gynecol Oncol 103 (2006) 797-801
29. Bookman M.A., McGuire III W.P., Kilpatrick D., Keenan E., Hogan W.M., Johnson S.W., et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14 (1996) 1895-1902
30. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18 (2000) 106-115
31. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 (2004) 650-654
32. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090